- Company
- Will Verzenio succeed in expanding benefits
- by Eo, Yun-Ho May 3, 2023 05:38am
- Attention is focusing on whether Verzenio will succeed in expanding early breast cancer insurance benefits. According to the related industry, the agenda to expand reimbursement for early breast cancer with a high recurrence risk of Verzenio, a breast cancer treatment with CDK4/6 inhibitory mechanism of Lilly Korea, is expected to be presente
- Company
- Boryung fails 3 of 5 patent challenges
- by Kim, Jin-Gu May 3, 2023 05:38am
- Boryung's omnidirectional patent challenge strategy on orignial anticancer drugs has been making slow progress. Since the end of 2021, Boryung filed patent challenges on 5 anticancer drugs, and lost or voluntarily withdrew 3 of those claims. Despite the strong drive it has been making for its anticancer drug business with plans to launch gene
- Company
- ‘Korea’s low reimb of orphan drugs needs to be improved’
- by Eo, Yun-Ho May 3, 2023 05:38am
- Study results have shown that Korea has low access to rare disease treatments. The Korean Research-based Pharmaceutical Industry Association (KRPIA) recently announced study results that stress Korea’s need to improve its reimbursement system in consideration of the characteristics held by rare diseases and rare disease treatments base
- Company
- Boryung signed a contract to establish a joint venture with
- by Kim, Jin-Gu May 2, 2023 05:36am
- Boryung announced on the 26th that it signed a contract to establish a joint venture (JV) with Axiom Space of the United States on the 25th (local time) to jointly promote the space business. Boryung CEO Kim Jeong-kyun, who visited the United States on an economic mission to the United States, signed a JV establishment contract with Axiom Spa
- Company
- Eylea Prefilled Syringe can be prescribed at GHs in KOR
- by Eo, Yun-Ho May 2, 2023 05:36am
- The pre-filled syringe formulation of Eylea can now be prescribed at general hospitals in Korea. According to industry sources, Bayer Korea's Wet Age-Related Macular Degeneration (wAMD) treatment 'Eylea Pre-filled Syringe,’ which was released with insurance reimbursement in October last year, has passed the drug committee reviews of tert
- Company
- Exkivity, an exon 20-targeted anti-cancer drug, can be presc
- by Eo, Yun-Ho May 2, 2023 05:35am
- Exkivity, an anticancer drug targeting EGFR exon 20 insertion mutations, can be prescribed at general hospitals. According to related industries, Exkivity, a treatment for non-small cell lung cancer with an EGFR exon 20 insertion mutation of Takeda Pharmaceutical Korea, passed the Drug Committees of the National Cancer Center, Seoul National
- Company
- Gilead’s HCV drug occupies 19% of HCV market in 5 mths
- by Kim, Jin-Gu May 2, 2023 05:35am
- Gilead Science’s new hepatitis C treatment has made a successful soft landing in the market and derived good initial results. Epclusa and Vosevi, which were released in November last year, increased their market share to 19% in the oral hepatitis C treatment market in Q1 this year. On the other hand, the market share of Abbvie’s Mavyre
- Company
- SK Bioscience, Investing 2.4 trillion won over 5 years
- by Kim, Jin-Gu Apr 30, 2023 09:46am
- SK Bioscience has decided to invest 2.4 trillion won over the next five years. SK Bioscience announced on the 27th at 2:00 pm that it would announce its mid-to-long-term growth strategy to stock analysts and institutional investors. According to the disclosure, SK bioscience will spend 2.4 trillion won over the five years from this year to
- Company
- Hanmi, sales and operating profits highest in 8 years
- by Chon, Seung-Hyun Apr 28, 2023 05:49am
- Hanmi Pharmaceutical showed improved performance in the first quarter. Thanks to the high growth of new combination drugs such as Rosuzet and Amosartan family, both sales and operating profit recorded the highest level in eight years. Hanmi Pharmaceutical announced on the 26th that its operating profit in the first quarter was 60.5 billion won,
- Company
- Dupixent attempts to expand its reimb to infants in KOR
- by Eo, Yun-Ho Apr 28, 2023 05:49am
- Dupixent is attempting to expand insurance reimbursement to infants after succeeding to reimburse the drug to children. Dailpharm’s coverage showed that Sanofi-Aventis Korea recently submitted an application for an extension of reimbursement for infants aged 6 months to 5 years of age for its atopic dermatitis treatment Dupixent (dupil
